Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.36 |
| ▸ | MTOR | P42345 | 2/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25663116 | 0.90 | TGFBR1 (0.33) | PIK3CAPIK3CDPIK3CBMTORPIK3CG | |
| SCHEMBL25663101 | 0.89 | PIK3CA (0.48) | PIK3CAPIK3CDPIK3CBMTORPIK3CG | |
| SCHEMBL25663106 | 0.87 | NPC1 (0.35) | PIK3CAPIK3CDPIK3CBMTORPIK3CG | |
| SCHEMBL25663102 | 0.86 | NPC1 (0.44) | PIK3CAPIK3CDPIK3CBMTORPIK3CG | |
| SCHEMBL25663256 | 0.85 | PIK3CA (0.38) | PIK3CAPIK3CDPIK3CBMTORPIK3CG | |
| SCHEMBL25663255 | 0.85 | PIK3CD (0.36) | PIK3CAPIK3CDPIK3CBMTORPIK3CG | |
| SCHEMBL25663257 | 0.84 | PIK3CA (0.40) | PIK3CAPIK3CDPIK3CBMTORPIK3CG | |
| SCHEMBL25663109 | 0.84 | TGFBR1 (0.39) | PIK3CAPIK3CDPIK3CBMTORPIK3CG | |
| SCHEMBL25663114 | 0.83 | NPC1 (0.37) | PIK3CAPIK3CDPIK3CBMTORPIK3CG | |
| SCHEMBL25663108 | 0.82 | NPC1 (0.40) | PIK3CAPIK3CDPIK3CBMTORPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172057-A1 | HETEROCYCLIC COMPOUND CONTAINING HETEROATOM SUBSTITUTED FLUORENE AND OPTOELECTRONIC DEVICE | WUHAN TIANMA MICRO-ELECTRONICS CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230172057-A1 | HETEROCYCLIC COMPOUND CONTAINING HETEROATOM SUBSTITUTED FLUORENE AND OPTOELECTRONIC DEVICE | WUHAN TIANMA MICRO-ELECTRONICS CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172057-A1 | HETEROCYCLIC COMPOUND CONTAINING HETEROATOM SUBSTITUTED FLUORENE AND OPTOELECTRONIC DEVICE | CHRM1, CHRM2, CHRM4 | PIK3CA 4539/4885PIK3CD 4761/4885PIK3CB 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.